From microscopes to molecules: The evolution of prostate cancer diagnostics

Junyue Tao; Xiaokang Bian; Jun Zhou; Meng Zhang

doi:10.25259/cytojournal_36_2024

journal article Aug 29, 2024

From microscopes to molecules: The evolution of prostate cancer diagnostics

Junyue Tao Xiaokang Bian Jun Zhou

Meng Zhang

Cytojournal Vol. 21 pp. 29 · Scientific Scholar

View at Publisher Save 10.25259/cytojournal_36_2024

Abstract

In the ever-evolving landscape of oncology, the battle against prostate cancer (PCa) stands at a transformative juncture, propelled by the integration of molecular diagnostics into traditional cytopathological frameworks. This synthesis not only heralds a new epoch of precision medicine but also significantly enhances our understanding of the disease’s genetic intricacies. Our comprehensive review navigates through the latest advancements in molecular biomarkers and their detection technologies, illuminating the potential these innovations hold for the clinical realm. With PCa persisting as one of the most common malignancies among men globally, the quest for early and precise diagnostic methods has never been more critical. The spotlight in this endeavor shines on the molecular diagnostics that reveal the genetic underpinnings of PCa, offering insights into its onset, progression, and resistance to conventional therapies. Among the genetic aberrations, the TMPRSS2-ERG fusion and mutations in genes such as phosphatase and tensin homolog (PTEN) and myelocytomatosis viral oncogene homolog (MYC) are identified as significant players in the disease’s pathology, providing not only diagnostic markers but also potential therapeutic targets. This review underscores a multimodal diagnostic approach, merging molecular diagnostics with cytopathology, as a cornerstone in managing PCa effectively. This strategy promises a future where treatment is not only tailored to the individual’s genetic makeup but also anticipates the disease’s trajectory, offering hope for improved prognosis and quality of life for patients.

Topics

No keywords indexed for this article. Browse by subject →

References

153

[1]

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al.

CA: A Cancer Journal for Clinicians 2021 10.3322/caac.21660

[2]

Cancer statistics, 2023

Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al.

CA: A Cancer Journal for Clinicians 2023 10.3322/caac.21763

[3]

Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches

Mamello Sekhoacha, Keamogetswe Riet, Paballo Motloung et al.

Molecules 2022 10.3390/molecules27175730

[4]

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

Gladell P. Paner, Walter M. Stadler, Donna E. Hansel et al.

European Urology 2018 10.1016/j.eururo.2017.12.018

[5]

Achard "Localized and locally advanced prostate cancer: Treatment options" Oncology (2021) 10.1159/000513258

[6]

Gillessen "Management of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the advanced prostate cancer consensus conference 2022" Eur Urol (2023) 10.1016/j.eururo.2022.11.002

[7]

Cai "Current therapy and drug resistance in metastatic castration-resistant prostate cancer" Drug Resist Update (2023) 10.1016/j.drup.2023.100962

[8]

Franklin "Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy" Pathology (2021) 10.1016/j.pathol.2020.10.009

[9]

Tang "Understanding and targeting prostate cancer cell heterogeneity and plasticity" Semin Cancer Biol (2022) 10.1016/j.semcancer.2021.10.001

[10]

Wei "Germline DNA repair gene mutation landscape in Chinese prostate cancer patients" Eur Urol (2019) 10.1016/j.eururo.2019.06.004

[11]

Goel "Epigenetic reprogramming during prostate cancer progression: A perspective from development" Semin Cancer Biol (2022) 10.1016/j.semcancer.2021.01.009

[12]

Ding "Role of noncoding RNA in drug resistance of prostate cancer" Cell Death Dis (2021) 10.1038/s41419-021-03854-x

[13]

Thunders "Gene of the month: TMPRSS2 (transmembrane serine protease 2)" J Clin Pathol (2020) 10.1136/jclinpath-2020-206987

[14]

Cruz-Hernandez "SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo" Cancer Cell Int (2020) 10.1186/s12935-020-01333-5

[15]

Kobelyatskaya "Transcriptome profiling of prostate cancer, considering risk groups and the TMPRSS2-ERG molecular subtype" Int J Mol Sci (2023) 10.3390/ijms24119282

[16]

Raina "Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models" Mol Carcinog (2022) 10.1002/mc.23413

[17]

Kish "The expression of proto-oncogene ETS-related gene (ERG) plays a central role in the oncogenic mechanism involved in the development and progression of prostate cancer" Int J Mol Sci (2022) 10.3390/ijms23094772

[18]

Gerke "Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma" Int J Cancer (2020) 10.1002/ijc.32792

[19]

Mosquera "Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications" Clin Cancer Res (2008) 10.1158/1078-0432.ccr-07-5194

[20]

Sanguedolce "Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: Literature review" Clin Genitourin Cancer (2016) 10.1016/j.clgc.2015.12.001

[21]

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment

Scott A. Tomlins, John R. Day, Robert J. Lonigro et al.

European Urology 2016 10.1016/j.eururo.2015.04.039

[22]

Rice "Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer" Clin Cancer Res (2010) 10.1158/1078-0432.ccr-09-2191

[23]

Leyten "Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer" Eur Urol (2014) 10.1016/j.eururo.2012.11.014

[24]

McLeod "Re. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer" Eur Urol (2018) 10.1016/j.eururo.2017.09.035

[25]

Sanda "Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer" JAMA Oncol (2017) 10.1001/jamaoncol.2017.0177

[26]

Alvarez-Garcia "Mechanisms of PTEN loss in cancer: It's all about diversity" Semin Cancer Biol (2019) 10.1016/j.semcancer.2019.02.001

[27]

Braglia "Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?" Biochim Biophys Acta Mol Cell Res (2020) 10.1016/j.bbamcr.2020.118731

[28]

Berger "The genomic complexity of primary human prostate cancer" Nature (2011) 10.1038/nature09744

[29]

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, Jaeil Ahn, Rehan Akbani et al.

Cell 2015 10.1016/j.cell.2015.10.025

[30]

Swamynathan "FABP5 inhibition against PTEN-mutant therapy resistant prostate cancer" Cancers (Basel) (2023) 10.3390/cancers16010060

[31]

Troyer "A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer" Prostate (2015) 10.1002/pros.23003

[32]

Yoshimoto "FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome" Br J Cancer (2007) 10.1038/sj.bjc.6603924

[33]

Punnoose "PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients" Br J Cancer (2015) 10.1038/bjc.2015.332

[34]

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer

Santosh Gupta, Daniel H. Hovelson, Gabor Kemeny et al.

Genes, Chromosomes and Cancer 2020 10.1002/gcc.22824

[35]

Jamaspishvili "Clinical implications of PTEN loss in prostate cancer" Nat Rev Urol (2018) 10.1038/nrurol.2018.9

[36]

Wang "PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: A systematic review and meta-analysis" Int J Clin Exp Med (2015)

[37]

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Renumathy Dhanasekaran, Anja Deutzmann, Wadie D. Mahauad-Fernandez et al.

Nature Reviews Clinical Oncology 2022 10.1038/s41571-021-00549-2

[38]

MYC on the Path to Cancer

Chi V. Dang

Cell 2012 10.1016/j.cell.2012.03.003

[39]

Trop-Steinberg "Is Myc an important biomarker? Myc expression in immune disorders and cancer" Am J Med Sci (2018) 10.1016/j.amjms.2017.06.007

[40]

Castro "High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers" Ann Oncol (2015) 10.1093/annonc/mdv356

[41]

Gurel "Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis" Mod Pathol (2008) 10.1038/modpathol.2008.111

[42]

Hawksworth "Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence" Prostate Cancer Prostatic Dis (2010) 10.1038/pcan.2010.31

[43]

Whitlock "MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity" Oncogene (2020) 10.1038/s41388-020-01389-7

[44]

Zhang "NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling" J Transl Med (2024) 10.1186/s12967-023-04834-9

[45]

Zafarana "Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy" Cancer (2012) 10.1002/cncr.26729

[46]

Wu "A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function" Prostate (2020) 10.1002/pros.23945

[47]

Yamamoto "Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth" Clin Cancer Res (2015) 10.1158/1078-0432.ccr-14-1108

[48]

The mutational landscape of lethal castration-resistant prostate cancer

Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al.

Nature 2012 10.1038/nature11125

[49]

Makino "Undesirable status of prostate cancer cells after intensive inhibition of AR signaling: Post-AR era of CRPC treatment" Biomedicines (2021) 10.3390/biomedicines9040414

[50]

Jacob "Androgen receptor signaling in prostate cancer and therapeutic strategies" Cancers (Basel) (2021) 10.3390/cancers13215417

Showing 50 of 153 references

Metrics

8

Citations

153

References

Details

Published: Aug 29, 2024
Vol/Issue: 21
Pages: 29

Authors

J

Junyue Tao

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China,

X

Xiaokang Bian

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China,

J

Jun Zhou

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China,

M

Meng Zhang

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China,

Cite This Article

Junyue Tao, Xiaokang Bian, Jun Zhou, et al. (2024). From microscopes to molecules: The evolution of prostate cancer diagnostics. Cytojournal, 21, 29. https://doi.org/10.25259/cytojournal_36_2024

From microscopes to molecules: The evolution of prostate cancer diagnostics

You May Also Like